Phase I Trial With Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab (PBO) for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine; Pentostatin
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 08 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2019.
- 03 Jun 2016 Status changed from recruiting to active, no longer recruiting.